Price$7.09+0.14 (+2.09%)
01:30 PM07:45 PM
News · 26 weeks72+80%
2026-03-012026-08-23
Mix3890d
- Insider13(34%)
- SEC Filings11(29%)
- Other9(24%)
- Offering2(5%)
- Analyst2(5%)
- Earnings1(3%)
Latest news
25 items- INSIDERCHIEF SCIENTIFIC OFFICER Hattersley Gary exercised 100,000 shares at a strike of $1.87 and sold $709,240 worth of shares (100,000 units at $7.09) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Nuvation BioCantor Fitzgerald initiated coverage of Nuvation Bio with a rating of Overweight
- PRNuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant GliomaDesignation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma Pivotal Phase 3 SIGMA study enrollment underway NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company's investigational, oral, brain-penetrant selective inhibitor of mutant IDH1. "People with IDH1
- SECSEC Form 144 filed by Nuvation Bio Inc.144 - Nuvation Bio Inc. (0001811063) (Subject)
- ANALYSTAnalyst initiated coverage on Nuvation Bio with a new price targetAnalyst initiated coverage of Nuvation Bio with a rating of Overweight and set a new price target of $13.00
- PRNuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateAchieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI® (taletrectinib)IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this settingAnnounced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant gliomaRobust balance sheet with cash, cash equivalents, and marketable securities of $661.0 million as of June 30, 2026; additional $36.5 million in
- SECSEC Form 8-K filed by Nuvation Bio Inc.8-K - Nuvation Bio Inc. (0001811063) (Filer)
- SECSEC Form 10-Q filed by Nuvation Bio Inc.10-Q - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual CongressesAnalyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroupsNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new analyses of long-term Phase 2 TRUST-I and TRUST-II data will be presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) taking place September 12–15, 2026, in Seoul, South Korea, and at the European Society of Medical Oncology Congress (ESMO) October 23–27, 2026, in Madrid, Spain. These findings from the pivotal Phase 2 studies will feature the efficacy and safety of IBTROZI® (ta
- PRNuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2026. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (U.S. toll-free) and enter ac
- PRNuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant GliomaUpdated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-upNew Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S.New Phase 2 study to evaluate safusidenib in patients whose glioma has progressed following treatment with vorasidenib in U.S.NEW YORK, July 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced updated positive long-term follow-up data from the Phase 2 (J201) study of safusidenib in patients with chemotherapy- and ra
- INSIDERChief Financial Officer Sauvage Philippe exercised 40,000 shares at a strike of $2.17, increasing direct ownership by 283% to 54,131 units (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- SECNuvation Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes OfferingNEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the "Greenshoe Exercise") to purchase an additional $37.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2032 (the "Notes"). The aggregate principal amount of Notes sold in the offering was $287.5 million, inclusive of the $37.5 million aggregate principal amount of Notes issued pursuant to the Greenshoe Exercise. On July 1, 2
- SECNuvation Bio Inc. filed SEC Form 8-K: Other Events, Entry into a Material Definitive Agreement8-K - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United KingdomFOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approvalNEW YORK, June 29, 2026 /PRNewswire/ -- Nuvation Bio (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has validated the Marketing Authorisation Application (MAA) submitted by its partner Eisai Co, Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell
- SECSEC Form 424B5 filed by Nuvation Bio Inc.424B5 - Nuvation Bio Inc. (0001811063) (Filer)
- SECSEC Form 305B2 filed by Nuvation Bio Inc.305B2 - Nuvation Bio Inc. (0001811063) (Filer)
- SECSEC Form FWP filed by Nuvation Bio Inc.FWP - Nuvation Bio Inc. (0001811063) (Subject)
- PRNuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior NotesNEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the "Notes"). The aggregate principal amount of the Offering was increased from the previously announced offering size of $200.0 million. The sale of the Notes to the underwriters is expected to close on June 30, 2026, subject to customary closing conditions. Nuvation Bio also granted the underwriters of the Notes a right to purchase, exercisable within 30 days
- SECSEC Form 424B5 filed by Nuvation Bio Inc.424B5 - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio Announces Proposed Convertible Senior Notes OfferingNEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the "Notes") in an underwritten offering (the "Offering"). Nuvation Bio also intends to grant the underwriters of the Notes a right to purchase, exercisable within 30 days of the date of the prospectus supplement relating to the Offering, up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if
- INSIDERCHIEF PEOPLE OFFICER Markel Stacy exercised 125,000 shares at a strike of $1.83 and sold $753,188 worth of shares (125,000 units at $6.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERCHIEF REGULATORY OFFICER Wentworth Kerry exercised 63,000 shares at a strike of $2.93 and sold $379,191 worth of shares (63,000 units at $6.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERChief Financial Officer Sauvage Philippe exercised 47,668 shares at a strike of $2.17 and sold $286,370 worth of shares (47,668 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Nuvation Bio Inc. (0001811063) (Issuer)
NUVB FAQ
7 questionsWhat does Nuvation Bio Inc. do?
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells...Where does NUVB stock trade?
Nuvation Bio Inc. (NUVB) is listed on NYSE.What sector and industry is NUVB in?
Nuvation Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nuvation Bio Inc. go public?
Nuvation Bio Inc. (NUVB) completed its IPO in 2020.What are analysts saying about NUVB?
Nuvation Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-08-21. Recent price targets range from $500.00 to $1300.00.What companies are similar to NUVB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NUVB side-by-side with any of them on Quantisnow.How can I track NUVB on Quantisnow?
Quantisnow aggregates Nuvation Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUVB to receive live email and push alerts on every new disclosure.